B+
Bull case
30%
Probability
Target price
$880.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
REGN
RegeneronCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$780.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$620.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.6
Score
AI commentary
This is a high-buzz T+1 earnings setup with a mixed tone: recent trusted-news headlines in the packet describe both an earnings beat and a share-price slide as investors focused on EYLEA pressure and the gross-margin outlook. Immediate post-print analyst revision evidence is not reliably available in the packet, and the peer set is too broad to support a standard-conviction relative-value call, so the memo should remain a tentative monitoring view rather than a bullish re-rate thesis.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-04-29eventQ1 beat offset by EYLEA mix pressure and lower gross-margin outlookMedium impact
Regeneron reported Q1 2026 revenue up 19% to $3.6 billion and non-GAAP EPS of $9.47, while total U.S. EYLEA HD plus EYLEA sales fell 10% year over year to $941 million. Management also lowered 2026 GAAP gross-margin guidance to 77%-78% from 79%-80% because of the temporary Limerick manufacturing interruption, which is expected to normalize by the end of Q2 2026. This keeps the earnings print mixed rather than cleanly bullish. [#8-K-2026-04-29] [#10-Q-2026-04-29]
2026-09-30catalystEYLEA HD conversion must outgrow legacy EYLEA erosionHigh impact
EYLEA HD U.S. sales rose 52% to $468 million and physician unit demand increased sequentially by 10%, helped by expanded dosing flexibility, but legacy EYLEA declined 36% and the company warned additional U.S. biosimilar competition is expected in the second half of 2026. The key medium-term question is whether EYLEA HD uptake can offset erosion across the broader retina franchise. [#10-Q-2026-04-29]
2026-12-31catalystDupixent and Libtayo strength continues to fund pipeline and buybacksHigh impact
Sanofi-recorded Dupixent global net sales increased 33% to $4.9 billion and Regeneron said its share of antibody commercialization profits rose to $1.451 billion, while global Libtayo sales increased 54% to $438 million. Alongside $18.5 billion of cash and marketable securities and a new $3.0 billion repurchase authorization, these franchises support ongoing late-stage investment even as retina pressure persists. [#8-K-2026-04-29] [#10-Q-2026-04-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology